Skip to content

Author

P. Tarantino

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Neoadjuvant antibody-drug conjugates for early-stage breast cancer: A systematic review and meta-analysis.

BACKGROUND Pathologic complete response (pCR) is a key endpoint of neoadjuvant therapy in early-stage breast cancer (EBC), associated with improved survival, particularly in triple-negative and human epidermal growth factor receptor 2 (HER2)-positive disease. More recently, antibody-drug conjugates (ADCs), established...

G. B. Silva, A. Simões, R. L. Nohmi et al. · 0 citations
Review Aug 2026

Antibody-drug conjugates in breast cancer: the first-line and curative setting.

PURPOSE OF REVIEW Antibody-drug conjugates (ADCs) have rapidly advanced from later-line salvage therapy into first-line metastatic and curative perioperative settings. This review appraises recent practice-changing data that collectively redefined treatment standards across Human epidermal growth factor receptor 2 (HER...

Nicole Odzer, P. Tarantino · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.